Evaluate the Efficacy and Safety of KI1107 in Patients Whose TG Level is Not Adequately Controlled With Rosuvastatin Calcium Monotherapy While LDL-C is Properly Controlled

NCT03026933 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

215

Enrollment

INDUSTRY

Sponsor class

Conditions

Dyslipidemias

Interventions

DRUG: KI1107 4 Capsules, QD
DRUG: Rosuvastatin Calcium 20 MG, QD

Sponsor

Kuhnil Pharmaceutical Co., Ltd.